Dermatology News and Research

Latest Dermatology News and Research

Diabetes may damage nerves in the skin leading to dry skin, say experts

As American Diabetes Month approaches, leading experts like Dr. Jacqueline Sutera, DPM, stress the importance of foot care, especially for those with diabetes. People with diabetes are at a greater risk of developing dry skin due to nerve damage.

30 Oct 2009

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.

29 Oct 2009

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced it led a $17.4 million Series B financing round for Quinnova Pharmaceuticals, Inc., with participation from existing investors Thomas, McNerney & Partners and H.I.G. BioVentures.

28 Oct 2009

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

Helix BioMedix, Inc., a developer of bioactive peptides, today announced the completion of a series of three clinical studies investigating the safety and efficacy of a serum, eye cream and moisturizer, each containing the Company’s SmartPeptides™ technology, including the newly developed Heptapeptide-7. These studies demonstrate improvement in skin texture and appearance as well as the decrease in fine lines and wrinkles with Striking™ Skin Care formulations.

28 Oct 2009

Global sales volumes of Levulan Kerastick exceed one million units

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

28 Oct 2009

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.

28 Oct 2009

IFPA urges WHO to act on new insights on psoriasis to help millions of psoriasis patients

October 29 is World Psoriasis Day. Conceived by patients for patients, World Psoriasis Day is a truly global event focusing on the burden of living with psoriasis. There are more than 125 million people with psoriasis/psoriatic arthritis in the world. Psoriasis is a severe chronic inflammatory disease that effects all ages, genders, races and ethnicities.

28 Oct 2009

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

PPD, Inc. today announced its board of directors has authorized management to proceed with preparations to spin off its compound partnering business from its core contract research organization, or CRO, business.

28 Oct 2009

NCI grant to conduct innovative cancer research

A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.

28 Oct 2009

SkinMedica enters into a global license agreement with New York University

SkinMedica, Inc. and New York University announced today that they have entered into a global license agreement to develop novel products to address skin hyperpigmentation based on technology invented at NYU.

27 Oct 2009

Dysport, a new wrinkle fighter, available now in the United States

The story: Dysport(TM), a new wrinkle fighter, is now available in the United States. Dysport(TM) is a Botulinum-A enzyme like Botox Cosmetic. Dysport(TM) is positioned as the new arch-nemesis and first direct competitor of Botox Cosmetic in the United States.

26 Oct 2009

Ceragenix Pharmaceuticals updates its cooperative research and development with MAST BioSurgery

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive cooperative research and development (the "Agreement”) with MAST BioSurgery Inc. (“MAST”) for the development of one or more new surgical products incorporating Ceragenix’s CeraShield™ antimicrobial technology.

26 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Halozyme Therapeutics, Inc. today announced dose response study results that demonstrated faster insulin absorption and increased peak insulin concentrations after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with regular human insulin and with insulin lispro. The enhanced absorption effects were observed at clinically relevant insulin doses across a broad range of PH20 concentrations.

22 Oct 2009

New corporate communication policy implemented at Senetek

Senetek PLC, a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that the Senetek Board of Directors has implemented a new Corporate Communication policy to insure that the highest standards of corporate governance are met and that full compliance with all public company regulations is in place.

22 Oct 2009

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche’s anticancer biologic, Herceptin (trastuzumab).

22 Oct 2009

Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions

Dermatologists agree that topical fixed-combination products containing clindamycin (clin) and benzoyl peroxide (BPO) are effective in the treatment of acne. However, products containing BPO concentrations at 5% or higher may limit use due to associated dryness and irritation in some patients.

22 Oct 2009

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

21 Oct 2009

New dual-port ophthalmic green laser photocoagulator introduced by IRIDEX

IRIDEX Corporation today announced the introduction of the IQ 532(TM) dual-port ophthalmic green laser photocoagulator which will be featured at the 2009 American Academy of Ophthalmology meeting in San Francisco.

21 Oct 2009

IRIDEX announces launch of a Modular Multi-Wavelength laser photocoagulator solution

IRIDEX Corporation today announced the introduction of a Modular Multi-Wavelength laser photocoagulator solution, which will be featured at the 2009 American Academy of Ophthalmology meeting in San Francisco.

21 Oct 2009

Dermatology News and Research

Latest Dermatology News and Research

Diabetes may damage nerves in the skin leading to dry skin, say experts

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

Global sales volumes of Levulan Kerastick exceed one million units

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

IFPA urges WHO to act on new insights on psoriasis to help millions of psoriasis patients

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

NCI grant to conduct innovative cancer research

SkinMedica enters into a global license agreement with New York University

Dysport, a new wrinkle fighter, available now in the United States

Ceragenix Pharmaceuticals updates its cooperative research and development with MAST BioSurgery

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

New corporate communication policy implemented at Senetek

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

New dual-port ophthalmic green laser photocoagulator introduced by IRIDEX

IRIDEX announces launch of a Modular Multi-Wavelength laser photocoagulator solution

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Dermatology News and Research

Latest Dermatology News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in